 Silence Therapeutics PLC LON:SLN, NASDAQ:SLN said it will receive US2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focused on the development and commercialisation of therapeutics that inhibit or silence the complement cascade, a group of proteins involved in the immune system that play a role in the development of inflammation. 